Phase 4, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of induction agents, alemtuzumab, basiliximab or rabbit anti-thymocyte globulin in combination with tacrolimus, MMF, and a rapid steroid withdrawal in renal transplant recipients.

Trial Profile

Phase 4, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of induction agents, alemtuzumab, basiliximab or rabbit anti-thymocyte globulin in combination with tacrolimus, MMF, and a rapid steroid withdrawal in renal transplant recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Basiliximab (Primary) ; Mycophenolate mofetil; Steroids; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms INTAC
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 19 May 2011 Results published in the New England Journal of Medicine.
    • 19 Aug 2010 Final 36-month results presented at the 23rd International Congress of the Transplantation Society.
    • 02 Jun 2010 Final 36-month results presented at the American Transplant Congress -- 10th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top